H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $77 from $66 and keeps a Buy rating on the shares following the gedatolisib data. The firm increased the probability of launch to 90% from 80%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC: